Immuneering (IMRX) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immuneering (IMRX) has outperformed Pyxis Oncology (PYXS) over the past year, losing 53.7% versus a loss of 62.3%. Over five years, IMRX leads with a -85.0% price change compared with -85.9% for PYXS. Immuneering is the larger company by market cap ($218.9 million vs $216.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | PYXS |
|---|---|---|
| Share price | $3.38 | $1.81 |
| Market cap | $218.90M | $216.49M |
| 1-day change | -2.03% | +7.74% |
| YTD return | -48.63% | +57.39% |
| 1-year return | -53.70% | -62.29% |
| 5-year return | -85.00% | -85.90% |
| EPS (TTM) | $-0.92 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $13.86M |
| Revenue growth (YoY) | — | -14.17% |
| Net income (latest FY) | $-56.02M | $-79.62M |
| Gross margin | — | 82.77% |
| Operating margin | — | -609.18% |
| Net margin | — | -574.55% |
| 52-week high | $8.48 | $5.55 |
| 52-week low | $3.29 | $1.03 |
| Distance from 52-week high | -60.14% | -67.39% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +402.96% | +354.14% |
| Average volume | 747.66K | 1.06M |
| Shares outstanding | 64.76M | 119.61M |
| Employees | 65 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
IMRX vs PYXS FAQ
Which is bigger, Immuneering or Pyxis Oncology?
Immuneering (IMRX) is larger, with a market capitalization of $218.90M compared with $216.49M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, IMRX or PYXS?
IMRX returned -53.70% over the past 12 months, compared with -62.29% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Immuneering and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.